Abstract
Under physiological conditions, the trans-presentation of interleukin-15 (IL-15) by the IL-15 receptor α on the cell surface allows to confine and tune the IL-15-mediated immune responses. Therefore, targeting strategies that mimic this situation at the tumor sites appear especially promising for anticancer immunotherapy.